Abstract | PURPOSE: Although olanzapine may have advantages over other second-generation antipsychotics (SGAs) regarding longer time to treatment discontinuation among chronically ill patients, little evidence has been provided for the comparative effectiveness of SGAs in the acute phase. We aimed to determine if any of four SGAs were more effective in treating newly admitted acute schizophrenic patients. We performed a rater-blinded, randomized controlled trial of four SGAs in 15 psychiatric emergency sites. Eligible patients were 18-64 years old and met diagnostic criteria for schizophrenia, acute schizophrenia-like psychotic disorder, or schizoaffective disorder. A final total of 78 patients were randomly assigned by means of sealed envelopes to receive risperidone (3-12 mg/day; n=20), olanzapine (10-20 mg/day; n=17), quetiapine (300-750 mg/day; n=20), or aripiprazole (12-30 mg/day; n=21), with follow-up at 8 weeks. The primary outcome measure was all-cause treatment discontinuation. RESULTS: CONCLUSION:
|
Authors | Kotaro Hatta, Koji Sato, Hiroshi Hamakawa, Hiroshi Takebayashi, Naoto Kimura, Shinichiro Ochi, Yasuhiko Sudo, Nozomu Asukai, Hiroyuki Nakamura, Chie Usui, Toshitaka Kawabata, Toyoaki Hirata, Yutaka Sawa |
Journal | Schizophrenia research
(Schizophr Res)
Vol. 113
Issue 1
Pg. 49-55
(Aug 2009)
ISSN: 1573-2509 [Electronic] Netherlands |
PMID | 19553086
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Analysis of Variance
- Antipsychotic Agents
(therapeutic use)
- Dose-Response Relationship, Drug
- Electrocardiography
(methods)
- Female
- Follow-Up Studies
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Outcome Assessment, Health Care
- Psychiatric Status Rating Scales
- Schizophrenia
(drug therapy, mortality, physiopathology)
- Schizophrenic Psychology
- Statistics, Nonparametric
- Young Adult
|